Liminatus Pharma, Inc.
LIMN
Analytical Summary
Liminatus Pharma, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.
3-Year Financial Trajectory
AnnualBullish Indicators
- Debt to EquityDebt to Equity is in the top quartile (lower is better)
- Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
Bearish Risks
- No bearish risks detected.
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| EPS Growth YoY (%) |
-115.0%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-187.8%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
-406.5%
Weak
Weak
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Return on Invested Capital (%) |
23.9%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
13.6%
Good
Good
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-578.8%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-61.6%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
104.0%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+593%)
|
18.3%
Good
Good
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+22%)
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Debt to Equity (x) |
-0.15x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-124%)
|
-1.03x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-272%)
|
— |
| Net Debt (USD) | $1.44M | $19.97M | — |
| Debt / EBITDA (x) |
-0.49x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
-6.00x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
— |
Secondary lens
Benchmark Lens
Compare LIMN against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare LIMN against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for LIMN
Debt to Equity is in the top quartile (lower is better)
Return on Common Equity (%) is in the top quartile
No bearish signals detected
Percentile Rankings
How LIMN compares to all companies
Peer Comparison
LIMN vs similar peers
Compare LIMN with peers
Stack LIMN against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 3 years · 10 quarters